News

Unique immune features found in AIHA may provide drug targets

While autoimmune hemolytic anemia (AIHA) — a group of disorders that includes cold agglutinin disease (CAD) — shares some immune features with other red blood cell-targeting diseases, its unique features might help researchers develop targeted therapies, a study reports. When analyzing the repertoire of immune B- and T-cell receptor…

Researchers call for standard antibody tests to diagnose CAD

Laboratories testing for cold agglutinins — the self-reactive antibodies causing cold agglutinin disease (CAD) — need to use standard protocols to provide accurate results, compare results between studies, and guide treatment, researchers said. “International standardization of CA [cold agglutinin] testing for diagnostic use is essential,” the researchers wrote.

Glucocorticoid therapy successfully treats man’s CAD: Case study

The glucocorticoid prednisolone successfully treated a man’s primary cold agglutinin disease (CAD), which is typically resistant to such therapies, a case report said. “Occasional” primary CAD cases “have demonstrated a favorable response” to glucocorticoids, “highlighting the need for a flexible and individualized therapeutic approach,” the researchers wrote. The case…

Enjaymo prior to major surgery can prevent CAD complications: Case

In people with cold agglutinin disease (CAD), pretreatment with Enjaymo (sutimlimab-jome) may limit disease-associated complications following urgent or planned surgeries in which a patient’s body temperature is considerably decreased. That’s according to a new report detailing the case of an 80-year-old woman in Japan for whom Enjaymo treatment before an…

Woman with CAD develops B-cell cancer during treatment

A woman with cold agglutinin disease (CAD) developed an aggressive B-cell lymphoma after having only a brief response to Enjaymo (sutimlimab), according to a case report. Researchers said the “case highlights the importance of reassessing underlying conditions through [a bone marrow biopsy] in cases where [Enjaymo] treatment is…

New ANX1502 tablet surpasses targeted blood levels in CAD trial

A new tablet formulation of Annexon Biosciences’ experimental therapy ANX1502 resulted in therapy levels in the blood that surpassed those expected to be effective in fasting participants with cold agglutinin disease (CAD). These results from a proof-of-concept study reflect a promising pharmacokinetic profile, which describes how the medication…